Cancer Productivity Disparities in the Asia-Pacific Region

New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect economic costs grew sharply in less-resourced settings, signalling an urgent need for prevention and early detection tailored to regional realities.

Middle-income Asia-Pacific geographies recorded a 47.7% rise in cancer deaths and a 42.3% increase in years of life lost, pushing the present value of future lost productivity to $3.2 billion. High-income areas, by contrast, saw deaths rise only 13.8% while their aggregate productivity losses actually fell 17.8% to $10.1 billion, as mortality shifted toward older age groups.

Valuing Lost Work Years

Researchers applied the human capital approach to Global Burden of Disease data, converting years of life lost and years lived with disability into monetary values. The model incorporated age-specific retirement ages, labour-force participation, unemployment rates, and sex-specific wages from World Bank and ILO sources. This produced four key metrics—years of productive life lost, present value of future lost productivity, productive years lived with disability, and their monetary equivalents—allowing consistent comparison across income groups and over time.

Contrasting Mortality and Morbidity Trends

Linear regression revealed a steep decline in years of life lost per death in both groups, yet the absolute burden grew dramatically in middle-income settings. Morbidity patterns diverged even more sharply: high-income countries achieved a slight reduction in disability per new case, whereas middle-income countries experienced rising disability intensity, especially from breast and cervical cancers. Sensitivity analyses confirmed that retirement-age assumptions exerted the strongest influence on overall estimates.

Cancer Productivity Asia-Pacific

These findings, drawn from a peer-reviewed analysis in the Journal of Medical Economics, underscore that health economics research must now prioritise localised evidence on early detection and survivorship programmes suitable for middle-income health systems. By embedding productivity metrics in national cancer control plans, policymakers can strengthen the economic case for sustained investment in prevention, timely access to innovation, and value-based reimbursement policies that reduce both clinical and societal burdens across the region.